Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder with an
initially chronic course lasting for 3–5 years. It eventually transforms into accelerated and …

All of the recombinant interferons are active agents for the systemic treatment of mycosis
fungoides and Sézary syndrome. The response rates are similar to those observed with …

The prognosis for patients with chronic myelogenous leukemia (CML) has changed
markedly since 1856, when the use of arsenicals (Fowler's solution) was first advocated in …

Recombinant interferon-α (rINF-α) is an immunomodulator used in the treatment of various
conditions, including viral infections and malignancies. The use of rINF-α has been …

Interferon‐induced sarcoidosis is well documented. We report two new cases of sarcoidosis
in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin. These …

Background: Since their initial use in the 1980s, IFNs have become an essential component
of the therapy for many diseases such as hepatitis and multiple sclerosis. Although they …

Interferons (IFNs) are class II cytokines that are key components of the innate immune
response to virus infection. Three IFN sub-families, type I, II, and III IFNs have been identified …

IFN-alpha2b has been used to treat patients with malignant melanoma who are at high risk
for recurrence after surgical resection. However, its exact mechanism of action is unknown. I …

Cytokines are now commonly used in the treatment of many conditions, especially cancer,
haematological malignancies and chronic viral hepatitis. With some of these cytokines …

The authors report the assessment of 2 patients on interferon alpha (IFN-alpha) therapy for
chronic myelogenous leukemia who developed manic symptoms long after IFN-alpha …